SCHEMBL915638

SCHEMBL915638

O=C1C(=Nc2ccc(-c3ccsc3)cc2)c2ccccc2N1c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 2/20 0.51
HTR4 Q13639 1/20 0.51
TTR P02766 4/20 0.48
MAPT P10636 5/20 0.46
NPSR1 Q6W5P4 2/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 2/20 0.43
CES2 O00748 1/20 0.43
BCHE P06276 1/20 0.43
GAA P10253 1/20 0.43
CES1 P23141 1/20 0.43
PDE6D O43924 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
LMNA P02545 1/20 0.41
CA12 O43570 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA1 P00915 1/20 0.41
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL915636 1.00 GALR3 (0.51) GALR3HTR4TTRMAPTNPSR1
SCHEMBL916865 0.89 TTR (0.49) GALR3HTR4TTRMAPTNPSR1
SCHEMBL916867 0.89 TTR (0.49) GALR3HTR4TTRMAPTNPSR1
SCHEMBL3237725 0.89 TTR (0.49) GALR3HTR4TTRMAPTNPSR1
SCHEMBL918425 0.81 TTR (0.47) GALR3HTR4TTRMAPTNPSR1
SCHEMBL918427 0.81 TTR (0.47) GALR3HTR4TTRMAPTNPSR1
SCHEMBL915899 0.80 TTR (0.62) GALR3HTR4TTRMAPTNPSR1
SCHEMBL917545 0.80 TTR (0.46) GALR3HTR4TTRMAPTNPSR1
SCHEMBL915901 0.80 TTR (0.62) GALR3HTR4TTRMAPTNPSR1
SCHEMBL917993 0.80 TTR (0.62) GALR3HTR4TTRMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198313-B2 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S (DK) 2012-06-12 US disclosed
US-20110178125-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS KONKEL MICHAEL 2011-07-21 US disclosed
US-7868034-B2 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S (DK) 2011-01-11 US disclosed
EP-2140864-A2 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods H.Lundbeck A/S (DK) 2010-01-06 EP disclosed
EP-2140862-A2 Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods H.Lundbeck A/S (DK) 2010-01-06 EP disclosed
US-20090318504-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods BLACKBURN THOMAS P 2009-12-24 US disclosed
US-20090176840-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS KONKEL MICHAEL 2009-07-09 US disclosed
US-7465750-B2 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S (US) 2008-12-16 US disclosed
US-20070259942-A1 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods BLACKBURN THOMAS P 2007-11-08 US disclosed
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-20070054910-A1 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods KONKEL MICHAEL 2007-03-08 US disclosed
US-7081470-B2 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S 2006-07-25 US disclosed
US-20040127502-A1 Use of GAL3 antagonist for treatment of depression SYNAPTIC PHARMACEUTICAL CORPORATION 2004-07-01 US disclosed
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative H. LUNDBECK A/S (DK) 2004-06-10 US disclosed
US-20040102507-A1 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S (DK) 2004-05-27 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed
US-20030078271-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods SYNAPTIC PHARMACEUTICAL CORPORATION 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318504-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR2, GALR1 GALR3 1/4885HTR4 30/4885TTR 4498/4885
US-20030078271-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR2, GALR1 GALR3 1/4885HTR4 30/4885TTR 4498/4885
US-20110178125-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS GALR3, GALR1, GALR2 GALR3 1/4885HTR4 30/4885TTR 4652/4885
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative GALR3, GALR2, GALR1 GALR3 1/4885HTR4 17/4885TTR 3477/4885
US-20040127502-A1 Use of GAL3 antagonist for treatment of depression GALR3, GALR2, GALR1 GALR3 1/4885HTR4 24/4885TTR 4307/4885
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain GALR3, GALR2, GALR1 GALR3 1/4885HTR4 214/4885TTR 4610/4885
US-20070054910-A1 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR1, GALR2 GALR3 1/4885HTR4 30/4885TTR 4652/4885
US-20090176840-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS GALR3, GALR1, GALR2 GALR3 1/4885HTR4 31/4885TTR 4645/4885
US-20040102507-A1 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR1, GALR2 GALR3 1/4885HTR4 30/4885TTR 4652/4885
US-20070259942-A1 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR2, GALR1 GALR3 1/4885HTR4 32/4885TTR 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.